Drug intelligence / Profile preview

Mirfulan

Development stage
Phase 4
Lead developer
Recordati
Modality
Small Molecules
Administration
Topical
01

Overview

Mirfulan is a multi-ingredient topical wound and healing ointment primarily composed of zinc oxide and cod liver oil. Developed by Merckle Recordati GmbH, it is indicated for the treatment of non-infected acute and subacute skin damage, including diaper dermatitis, skin wounds, and conditions accompanied by redness, itching, and pain. The formulation leverages the astringent and protective properties of zinc oxide alongside the regenerative support of cod liver oil (rich in Vitamins A and D3) and urea. It is marketed in Germany as a pharmacy-only product and has been evaluated in clinical settings for its efficacy in improving transepidermal water loss (TEWL) and accelerating the healing of suction blister wounds.

Brand names
MirfulanMirfulan Spray N
Other names
Mirfulan ointment
02

Targets

KRT (Keratin and other superficial epidermal proteins)RARA (Retinoic acid receptor alpha)RARB (Retinoic acid receptor beta)RARG (Retinoic acid receptor gamma)RXRA (Retinoid X receptor alpha)RXRB (Retinoid X receptor beta)RXRG (RXRγ)VDR (Vitamin D receptor)RAR (Retinoic acid receptor)

Beyond the preview

Go deeper on Mirfulan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mirfulan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call